- Page 1 and 2: METHODS IN MOLECULAR BIOLOGY 360 T
- Page 3 and 4: M E T H O D S I N M O L E C U L A R
- Page 5 and 6: © 2007 Humana Press Inc. 999 River
- Page 7 and 8: vi Preface get. Approaches to targe
- Page 9 and 10: viii Contents 10 Transgenic Animal
- Page 11 and 12: x Contributors SAHOHIME MATSUMOTO
- Page 13 and 14: xii Contents of Volume 2 12 Validat
- Page 15 and 16: 2 Sioud disease pathogenesis and pe
- Page 17 and 18: 4 Sioud A more fruitful approach fo
- Page 19 and 20: 6 Sioud both transient and permanen
- Page 21 and 22: 8 Sioud serum biomarkers. This syne
- Page 23 and 24: 10 Sioud Fig. 2. Schematic of targe
- Page 25 and 26: 12 Sioud 13. Magin, T. M. (1998) Le
- Page 28 and 29: Harnessing the Human Genome 15 The
- Page 30 and 31: Harnessing the Human Genome 17 Fig.
- Page 32 and 33: Harnessing the Human Genome 19 Fig.
- Page 34 and 35: Harnessing the Human Genome 21 Fig.
- Page 36 and 37: Harnessing the Human Genome 23 The
- Page 38 and 39: Harnessing the Human Genome 25 Fig.
- Page 40 and 41: Harnessing the Human Genome 27 repr
- Page 42 and 43: Harnessing the Human Genome 29 14.
- Page 46 and 47: 3 Analysis of Gene Networks for Dru
- Page 48 and 49: Gene Networks 35 Fig. 1. Conceptual
- Page 50 and 51: Gene Networks 37 Table 1 List of 12
- Page 52 and 53: Gene Networks 39 Fig. 4. Downstream
- Page 54 and 55: Gene Networks 41 Fig. 6. Directed a
- Page 56 and 57: Gene Networks 43 where Γ ( . ) is
- Page 58 and 59: Gene Networks 45 r is the dimension
- Page 60 and 61: Gene Networks 47 Table 2 Druggable
- Page 62 and 63: Gene Networks 49 network and nonpar
- Page 64 and 65: Gene Networks 51 Fig. 9. (A) Identi
- Page 66 and 67: Gene Networks 53 Bayesian network w
- Page 68 and 69: Gene Networks 55 23. Tinerey, L. an
- Page 70 and 71: 4 Target Discovery and Validation i
- Page 72 and 73: Pancreatic Cancer 59 on the microar
- Page 74 and 75: Pancreatic Cancer 61 1.4. Mass Spec
- Page 76 and 77: Pancreatic Cancer 63 3. Yeast tRNA
- Page 78 and 79: Pancreatic Cancer 65 2.2.10. Purifi
- Page 80 and 81: Pancreatic Cancer 67 3. Methods 3.1
- Page 82 and 83: Pancreatic Cancer 69 3.1.5. Washing
- Page 84 and 85: Pancreatic Cancer 71 3.2.4. Ligatin
- Page 86 and 87: Pancreatic Cancer 73 3.2.9. Isolati
- Page 88 and 89: Pancreatic Cancer 75 14. Vortex the
- Page 90 and 91: Pancreatic Cancer 77 11. Incubate o
- Page 92 and 93: Pancreatic Cancer 79 Approximately
- Page 94 and 95:
Pancreatic Cancer 81 in many ways.
- Page 96 and 97:
Pancreatic Cancer 83 3.3.10. Sample
- Page 98 and 99:
Pancreatic Cancer 85 can be achieve
- Page 100 and 101:
Pancreatic Cancer 87 19. Argani, P.
- Page 102:
Pancreatic Cancer 89 49. Rabilloud,
- Page 105 and 106:
92 Sørlie
- Page 107 and 108:
94 Sørlie are based on such a plat
- Page 109 and 110:
Fig. 2. Cluster analysis of a subse
- Page 111 and 112:
98 Sørlie are not internally heter
- Page 113 and 114:
100 Sørlie termed luminal subtype
- Page 115 and 116:
102 Sørlie Fig. 4. Kaplan-Meier an
- Page 117 and 118:
104 Sørlie this cluster of genes v
- Page 119 and 120:
106 Sørlie Fig. 5. Cluster of gene
- Page 121 and 122:
108 Sørlie Fig. 6. Concordance bet
- Page 123 and 124:
110 Sørlie Acknowledgments All col
- Page 125 and 126:
112 Sørlie 31. Slamon, D. J., Clar
- Page 127 and 128:
114 Sørlie 62. Bergh, J., Norberg,
- Page 129 and 130:
116 Røsok and Sioud 1.1. Selection
- Page 131 and 132:
118 Røsok and Sioud Compared with
- Page 133 and 134:
120 Røsok and Sioud 1.1.7. Differe
- Page 135 and 136:
122 Røsok and Sioud a powerful app
- Page 137 and 138:
124 Røsok and Sioud represent each
- Page 139 and 140:
126 Røsok and Sioud splicing may b
- Page 141 and 142:
128 Røsok and Sioud 22. Liang, P.
- Page 144 and 145:
7 Genome-Wide Screening by Using Sm
- Page 146 and 147:
RNAi Libraries 133 Fig. 2. Schemati
- Page 148 and 149:
RNAi Libraries 135 pathways. Thus,
- Page 150 and 151:
RNAi Libraries 137 3.3.1. Puromysin
- Page 152 and 153:
RNAi Libraries 139 Fig. 4. Example
- Page 154 and 155:
RNAi Libraries 141 12. Paddison, P.
- Page 156 and 157:
8 Hammerhead Ribozyme-Based Target
- Page 158 and 159:
Hammerhead Ribozymes 145 Libraries
- Page 160 and 161:
Hammerhead Ribozymes 147 3.1.1. Pre
- Page 162 and 163:
149 Fig. 2. Discovery of genes invo
- Page 164 and 165:
Hammerhead Ribozymes 151 3.3. Recov
- Page 166:
Hammerhead Ribozymes 153 9. Onuki,
- Page 169 and 170:
156 Erfle and Pepperkok 2. Material
- Page 171 and 172:
158 Erfle and Pepperkok cells away
- Page 173 and 174:
160 Erfle and Pepperkok 5. The stai
- Page 176 and 177:
10 Transgenic Animal Models in Biom
- Page 178 and 179:
Transgenic Models 165 giant mice ex
- Page 180 and 181:
Transgenic Models 167 2.1.3. Use of
- Page 182 and 183:
Transgenic Models 169 a recombinant
- Page 184 and 185:
Transgenic Models 171 Fig. 3. Diffe
- Page 186 and 187:
Transgenic Models 173 FRT sites are
- Page 188 and 189:
Transgenic Models 175 Fig. 4. Diffe
- Page 190 and 191:
Transgenic Models 177 models, the b
- Page 192 and 193:
Transgenic Models 179 Fig. 6. Vecto
- Page 194 and 195:
Transgenic Models 181 vectors can d
- Page 196 and 197:
Transgenic Models 183 then used to
- Page 198 and 199:
Transgenic Models 185 be fixed and
- Page 200 and 201:
Transgenic Models 187 period of inc
- Page 202 and 203:
Transgenic Models 189 (142). Genes
- Page 204 and 205:
Transgenic Models 191 from differen
- Page 206 and 207:
Transgenic Models 193 Acknowledgmen
- Page 208 and 209:
Transgenic Models 195 34. Thermes,
- Page 210 and 211:
Transgenic Models 197 68. Gupta, S.
- Page 212 and 213:
Transgenic Models 199 105. Weber, W
- Page 214 and 215:
Transgenic Models 201 138. Ranger,
- Page 216 and 217:
11 Keratin Transgenic and Knockout
- Page 218 and 219:
Keratin Transgenics and Knockouts 2
- Page 220 and 221:
Keratin Transgenics and Knockouts 2
- Page 222 and 223:
Keratin Transgenics and Knockouts 2
- Page 224 and 225:
211 K17 K17 Hair follicles, Alopeci
- Page 226 and 227:
213 K6a K6a Hair follicles; Lysis o
- Page 228 and 229:
Keratin Transgenics and Knockouts 2
- Page 230 and 231:
Keratin Transgenics and Knockouts 2
- Page 232 and 233:
Keratin Transgenics and Knockouts 2
- Page 234 and 235:
Keratin Transgenics and Knockouts 2
- Page 236 and 237:
Keratin Transgenics and Knockouts 2
- Page 238 and 239:
Keratin Transgenics and Knockouts 2
- Page 240 and 241:
Keratin Transgenics and Knockouts 2
- Page 242 and 243:
Keratin Transgenics and Knockouts 2
- Page 244 and 245:
Keratin Transgenics and Knockouts 2
- Page 246 and 247:
Keratin Transgenics and Knockouts 2
- Page 248 and 249:
Keratin Transgenics and Knockouts 2
- Page 250 and 251:
Keratin Transgenics and Knockouts 2
- Page 252 and 253:
Keratin Transgenics and Knockouts 2
- Page 254 and 255:
Keratin Transgenics and Knockouts 2
- Page 256 and 257:
Keratin Transgenics and Knockouts 2
- Page 258 and 259:
Keratin Transgenics and Knockouts 2
- Page 260 and 261:
Keratin Transgenics and Knockouts 2
- Page 262 and 263:
Keratin Transgenics and Knockouts 2
- Page 264:
Keratin Transgenics and Knockouts 2
- Page 267:
254 Skovseth, Küchler, and Haralds
- Page 270 and 271:
In Vivo Assay of Human Angiogenesis
- Page 272 and 273:
In Vivo Assay of Human Angiogenesis
- Page 274 and 275:
In Vivo Assay of Human Angiogenesis
- Page 276 and 277:
In Vivo Assay of Human Angiogenesis
- Page 278 and 279:
In Vivo Assay of Human Angiogenesis
- Page 280 and 281:
In Vivo Assay of Human Angiogenesis
- Page 282 and 283:
13 A Murine Model for Studying Hema
- Page 284 and 285:
Heart Failure and Immunity 271 We h
- Page 286 and 287:
Heart Failure and Immunity 273 3.1.
- Page 288:
Heart Failure and Immunity 275 6. W
- Page 291 and 292:
278 Sioud gene products have been d
- Page 293 and 294:
280 Sioud Fig. 1. Schematic of hema
- Page 295 and 296:
282
- Page 297 and 298:
284
- Page 299 and 300:
286 Sioud selection), whereas thymo
- Page 301 and 302:
288 Sioud Fig. 5. Affinity maturati
- Page 303 and 304:
290 Sioud Fig. 6. A second signal i
- Page 305 and 306:
292 Sioud Fig. 7. Bridging between
- Page 307 and 308:
294 Sioud Fig. 8. Schematic of clas
- Page 309 and 310:
296 Sioud Fig. 10. Critical molecul
- Page 311 and 312:
298 Sioud In contrast to the expres
- Page 313 and 314:
300 Sioud tumor infiltrating lympho
- Page 315 and 316:
302 Sioud (see Chapter 15, Volume 1
- Page 317 and 318:
304 Sioud display if the foreign pr
- Page 319 and 320:
306 Sioud Fig. 13. Immunoscreening
- Page 321 and 322:
308 Sioud molecular techniques have
- Page 323 and 324:
310 Sioud Although much of the init
- Page 325 and 326:
312 Sioud Because of their importan
- Page 327 and 328:
314 Sioud 22. He, X., Janeway, C. A
- Page 329 and 330:
316 Sioud 59. Sahin, U., Tureci, O.
- Page 331 and 332:
318 Sioud 91. Golgher, D., Jones, E
- Page 333 and 334:
320 Jäger Furthermore, this immune
- Page 335 and 336:
322 Jäger Antigens that are tumor-
- Page 337 and 338:
324 Jäger 2. Nakano, O., Sato, M.,
- Page 339 and 340:
326 Jäger 31. Chen, Y. T., Gure, A
- Page 341 and 342:
328 Le Naour dependent on CD8+ cyto
- Page 343 and 344:
330 Le Naour Fig. 1. To illustrate
- Page 345 and 346:
332 Le Naour heterogeneity of HCC,
- Page 347 and 348:
334 Le Naour 15. Le Naour, F., Mise
- Page 349 and 350:
336 Cekaite, Hovig, and Sioud Yeast
- Page 351 and 352:
338 Cekaite, Hovig, and Sioud diffe
- Page 353 and 354:
340
- Page 355 and 356:
342 Cekaite, Hovig, and Sioud nonra
- Page 357 and 358:
344 Cekaite, Hovig, and Sioud 3. Ue
- Page 359 and 360:
346 Cekaite, Hovig, and Sioud 32. T
- Page 361 and 362:
348 Cekaite, Hovig, and Sioud 65. L
- Page 363 and 364:
350 Index Centroblast, 289 Centrocy
- Page 365 and 366:
352 Index L Labeling mRNA, 62 Large
- Page 367:
354 Index Tetraploid embryos, 239 g